Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
RGLS's Cash to Debt is ranked higher than
77% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. RGLS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
RGLS' s Cash to Debt Range Over the Past 10 Years
Min: 1.76  Med: 9.68 Max: No Debt
Current: No Debt
Equity to Asset 0.84
RGLS's Equity to Asset is ranked higher than
79% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. RGLS: 0.84 )
Ranked among companies with meaningful Equity to Asset only.
RGLS' s Equity to Asset Range Over the Past 10 Years
Min: -1.26  Med: 0.72 Max: 0.89
Current: 0.84
-1.26
0.89
F-Score: 4
Z-Score: 6.03
M-Score: -3.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -371.10
RGLS's Operating margin (%) is ranked lower than
64% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. RGLS: -371.10 )
Ranked among companies with meaningful Operating margin (%) only.
RGLS' s Operating margin (%) Range Over the Past 10 Years
Min: -585.6  Med: -139.60 Max: -51.76
Current: -371.1
-585.6
-51.76
Net-margin (%) -366.42
RGLS's Net-margin (%) is ranked lower than
65% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. RGLS: -366.42 )
Ranked among companies with meaningful Net-margin (%) only.
RGLS' s Net-margin (%) Range Over the Past 10 Years
Min: -739.08  Med: -158.99 Max: -55.13
Current: -366.42
-739.08
-55.13
ROE (%) -49.06
RGLS's ROE (%) is ranked lower than
58% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. RGLS: -49.06 )
Ranked among companies with meaningful ROE (%) only.
RGLS' s ROE (%) Range Over the Past 10 Years
Min: -169.02  Med: -46.91 Max: -24
Current: -49.06
-169.02
-24
ROA (%) -42.92
RGLS's ROA (%) is ranked lower than
59% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. RGLS: -42.92 )
Ranked among companies with meaningful ROA (%) only.
RGLS' s ROA (%) Range Over the Past 10 Years
Min: -38.49  Med: -35.46 Max: -16.48
Current: -42.92
-38.49
-16.48
ROC (Joel Greenblatt) (%) -913.61
RGLS's ROC (Joel Greenblatt) (%) is ranked lower than
62% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. RGLS: -913.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RGLS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1544.17  Med: -534.92 Max: -450.68
Current: -913.61
-1544.17
-450.68
Revenue Growth (3Y)(%) -36.10
RGLS's Revenue Growth (3Y)(%) is ranked lower than
82% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. RGLS: -36.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RGLS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -89.60 Max: -36.1
Current: -36.1
EBITDA Growth (3Y)(%) -18.80
RGLS's EBITDA Growth (3Y)(%) is ranked lower than
70% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. RGLS: -18.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RGLS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -73.70 Max: -18.8
Current: -18.8
EPS Growth (3Y)(%) -20.00
RGLS's EPS Growth (3Y)(%) is ranked lower than
69% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. RGLS: -20.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RGLS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -75.30 Max: -20
Current: -20
» RGLS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-07)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

RGLS Guru Trades in

RGLS Guru Trades in

Q2 2015

RGLS Guru Trades in Q2 2015

Jim Simons 57,000 sh (New)
» More
Q3 2015

RGLS Guru Trades in Q3 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with RGLS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.57
RGLS's P/B is ranked higher than
64% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. RGLS: 2.57 )
Ranked among companies with meaningful P/B only.
RGLS' s P/B Range Over the Past 10 Years
Min: 2.45  Med: 3.95 Max: 12.95
Current: 2.57
2.45
12.95
P/S 15.74
RGLS's P/S is ranked lower than
56% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. RGLS: 15.74 )
Ranked among companies with meaningful P/S only.
RGLS' s P/S Range Over the Past 10 Years
Min: 0.1  Med: 19.79 Max: 111.09
Current: 15.74
0.1
111.09
EV-to-EBIT -2.60
RGLS's EV-to-EBIT is ranked lower than
99.99% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.28 vs. RGLS: -2.60 )
Ranked among companies with meaningful EV-to-EBIT only.
RGLS' s EV-to-EBIT Range Over the Past 10 Years
Min: -24.9  Med: -7.50 Max: 3.1
Current: -2.6
-24.9
3.1
EV-to-EBITDA -2.67
RGLS's EV-to-EBITDA is ranked lower than
99.99% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 20.97 vs. RGLS: -2.67 )
Ranked among companies with meaningful EV-to-EBITDA only.
RGLS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -25.9  Med: -8.10 Max: 3.2
Current: -2.67
-25.9
3.2
Current Ratio 10.51
RGLS's Current Ratio is ranked higher than
77% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. RGLS: 10.51 )
Ranked among companies with meaningful Current Ratio only.
RGLS' s Current Ratio Range Over the Past 10 Years
Min: 1.64  Med: 9.24 Max: 12.36
Current: 10.51
1.64
12.36
Quick Ratio 10.51
RGLS's Quick Ratio is ranked higher than
78% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. RGLS: 10.51 )
Ranked among companies with meaningful Quick Ratio only.
RGLS' s Quick Ratio Range Over the Past 10 Years
Min: 1.64  Med: 9.24 Max: 12.36
Current: 10.51
1.64
12.36
Days Sales Outstanding 1.31
RGLS's Days Sales Outstanding is ranked lower than
86% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. RGLS: 1.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
RGLS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.47  Med: 13.04 Max: 176.2
Current: 1.31
1.47
176.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 2.66
RGLS's Price/Tangible Book is ranked higher than
70% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. RGLS: 2.66 )
Ranked among companies with meaningful Price/Tangible Book only.
RGLS' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.74  Med: 4.29 Max: 7.36
Current: 2.66
2.74
7.36
Earnings Yield (Greenblatt) (%) -38.50
RGLS's Earnings Yield (Greenblatt) (%) is ranked lower than
78% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. RGLS: -38.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RGLS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 32.8  Med: 39.35 Max: 44.4
Current: -38.5
32.8
44.4

More Statistics

Revenue(Mil) $21
EPS $ -1.09
Beta2.02
Short Percentage of Float16.31%
52-Week Range $5.14 - 14.50
Shares Outstanding(Mil)52.78

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 6 6 40
EPS($) -1.29 -1.49 -1.12
EPS without NRI($) -1.29 -1.49 -1.12

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:RPTP, NAS:ARNA, NAS:BPMC, NAS:XBIT, XKRX:031390, XKRX:049960 » details
Traded in other countries:7RG.Germany,
Regulus Therapeutics Inc. was incorporated in the State of Delaware. It is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a broad range of diseases. The Company was formed in 2007 when Alnylam Pharmaceuticals, Inc., or Alnylam, and Isis Pharmaceuticals, Inc., or Isis, contributed significant intellectual property, know-how and financial and human capital to pursue the development of drugs targeting microRNAs pursuant to a license and collaboration agreement. microRNAs are recently discovered, naturally occurring ribonucleic acid, or RNA, molecules that play a critical role in regulating key biological pathways. Scientific research has shown the improper balance, or dysregulation, of microRNAs is directly linked to many diseases. The Company benefits substantially from the collective therapeutic RNA expertise of its founding companies, including established proprietary oligonucleotide-based technologies, and broad and dominant intellectual property estates specific to chemically modified oligonucleotides. The Company has exclusive rights to over 900 patents and patent applications pertaining to oligonucleotide modifications, conjugates, and design patterns, all for use in targeting microRNA for therapeutic applications. The microRNA therapeutics are oligonucleotide medicines that modulate the function of microRNAs, correcting the imbalance of gene expression and associated cellular pathways to treat human disease. It is currently optimizing anti-miRs targeting miR-21, miR-122, miR-33 and miR-10b for development candidate selection. It has established strategic alliances with AstraZeneca, GSK and Sanofi and it will continue to seek partners who can bring therapeutic expertise, development and commercialization capabilities and funding to allow it to maximize the potential of its microRNA product platform. Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those it is developing.
» More Articles for NAS:RGLS

Headlines

Articles On GuruFocus.com
Top Insider Buys, Sells of the Week Feb 26 2016 
Weekly CEO Sells Highlight: Hovnanian Enterprises Inc, Regulus Therapeutics Inc, Monster Beverage Co Apr 27 2015 
Regulus Therapeutics (RGLS) microRNA Therapeutic Milestone Payment, Dave & Buster's Entertainment (P Apr 08 2015 
This Week’s Pharma Highlights Mar 19 2015 
Weekly CEO Sells Highlight: Kimberly-Clark Corp, Regulus Therapeutics Inc, Prologis Inc, and Adobe S Feb 01 2015 

More From Other Websites
Regulus Therapeutics, Inc. :RGLS-US: Earnings Analysis: Q1, 2016 By the Numbers May 05 2016
Regulus to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference May 04 2016
Regulus to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference May 04 2016
REGULUS THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report May 03 2016
Edited Transcript of RGLS earnings conference call or presentation 2-May-16 9:00pm GMT May 02 2016
Regulus Therapeutics Inc Earnings Call scheduled for 5:00 pm ET today May 02 2016
Regulus reports 1Q loss May 02 2016
Regulus reports 1Q loss May 02 2016
Regulus Reports First Quarter 2016 Financial Results and Recent Highlights May 02 2016
REGULUS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 02 2016
Regulus Reports First Quarter 2016 Financial Results and Recent Highlights May 02 2016
Q1 2016 Regulus Therapeutics Inc Earnings Release - After Market Close May 02 2016
Regulus Announces Timing for First Quarter 2016 Financial Results Webcast and Conference Call Apr 26 2016
Regulus Announces Timing for First Quarter 2016 Financial Results Webcast and Conference Call Apr 26 2016
Regulus Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RGLS-US : April... Apr 19 2016
What’s Going On With These 5 Trending Stocks? Apr 15 2016
Regulus Presents Additional Interim Data on RG-101 at International Liver Congress™ (ILC 2016) Apr 15 2016
Regulus Presents Additional Interim Data on RG-101 at International Liver Congress™ (ILC 2016) Apr 15 2016
Coverage initiated on Regulus Therapeutics by Chardan Capital Markets Apr 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK